Journal of Family Planning and Reproductive Health Care最新文献

{"title":"Deep implant insertions and ethyl chloride.","authors":"Ewan Bumpstead","doi":"10.1136/jfprhc-2017-101852","DOIUrl":"https://doi.org/10.1136/jfprhc-2017-101852","url":null,"abstract":"","PeriodicalId":15734,"journal":{"name":"Journal of Family Planning and Reproductive Health Care","volume":" ","pages":"346"},"PeriodicalIF":0.0,"publicationDate":"2017-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1136/jfprhc-2017-101852","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35373640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In this issue","authors":"","doi":"10.1136/jfprhc-2017-101910","DOIUrl":"https://doi.org/10.1136/jfprhc-2017-101910","url":null,"abstract":"","PeriodicalId":15734,"journal":{"name":"Journal of Family Planning and Reproductive Health Care","volume":"43 1","pages":"247 - 248"},"PeriodicalIF":0.0,"publicationDate":"2017-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1136/jfprhc-2017-101910","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48943824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incentivising contraceptive use: a helping hand or a push in the wrong direction?","authors":"Georgeina L Jarman","doi":"10.1136/jfprhc-2017-101893","DOIUrl":"https://doi.org/10.1136/jfprhc-2017-101893","url":null,"abstract":"Contraception is essential to allow women control over their bodies and to fulfil their sexual and reproductive health rights. Despite this, in 2014 the World Health Organization (WHO) estimated that 222 million women and adolescent girls were living without modern contraception, mainly affecting vulnerable groups within society.1 A number of schemes have emerged to address this need for increased contraceptive access in marginalised groups of women. These include incentivising programmes, where a reward is offered in return for use of a contraceptive. Enticing people into any medical intervention invites ethical analysis as the incentive may coerce the individual into a decision that they may not otherwise have made. Coercion threatens informed consent by undermining voluntary decision-making. Thus, using the widely accepted Four Principles of biomedical ethics, beneficence, justice, non-maleficence and autonomy,2 I will assess whether two high-income-setting-based contraceptive incentivising programmes, chosen as examples, could be seen as disregarding the autonomy of the women they are supposedly trying to help.\u0000\u0000The US-based Project Prevention is a non-profit organisation that has garnered much publicity since its founding by Barbara Harris in 1997, following her adoption of four children born to a mother with crack cocaine addiction. The organisation offers a substantial cash incentive (US$300) to drug-addicted women in return for use of a long-acting reversible contraceptive (LARC) or a sterilisation procedure.3 Offering cash incentives to women fuelling a drug habit raises difficult ethical questions: some would claim that this could be looked upon as coercion and a threat to human rights.\u0000\u0000On the other side of the Atlantic lies Pause, a UK-based programme that offers support to women who have had children taken into care, and who are at risk of future custodial losses. One of the conditions of entering the programme is for women to use a LARC. In …","PeriodicalId":15734,"journal":{"name":"Journal of Family Planning and Reproductive Health Care","volume":" ","pages":"331-334"},"PeriodicalIF":0.0,"publicationDate":"2017-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1136/jfprhc-2017-101893","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35439548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing two regimens of intravaginal misoprostol with intravaginal gemeprost for second-trimester pregnancy termination: a randomised controlled trial.","authors":"Daniel Seow Choon Koh,&nbsp;Esther Pei Jing Ang,&nbsp;Jurja Chua Coyuco,&nbsp;Hua Zhen Teo,&nbsp;Xiaoling Huang,&nbsp;Xing Wei,&nbsp;Mor Jack Ng,&nbsp;Serene Liqing Lim,&nbsp;Kok Hian Tan","doi":"10.1136/jfprhc-2016-101652","DOIUrl":"https://doi.org/10.1136/jfprhc-2016-101652","url":null,"abstract":"<p><strong>Aim: </strong>To compare the efficacy and safety of intravaginal misoprostol 200 µg, 400 µg and gemeprost regimens for second-trimester termination of pregnancy (TOP).</p><p><strong>Methods: </strong>A three- armed randomi sed controlled trial (Clinical Trial Certificate 1100015) where 116 women undergoing second-trimester TOP were given intravaginal misoprostol 200 µ g (<i>n</i>=37), misoprostol 400 µg (<i>n</i>=40) or gemeprost 1 mg (<i>n</i>=39) at 4- hour intervals until abortion occurred with a maximum of five doses.</p><p><strong>Results: </strong>The misoprostol 400 µg group had the highest incidence of successful abortions (92.5%) compared to the misoprostol 200 µg (70.3%; <i>p</i>=0.017) and gemeprost 1 mg (74.4%; <i>p</i>=0.037) within 48 hours. There was no significant difference in abortion rate between misoprostol 200 µg and gemeprost. The misoprostol 400 µg group had the highest incidence of fever (70.0%) compared to misoprostol 200 µg (24.3%; <i>p</i><0.001) and gemeprost 1 mg (46.2%; <i>p</i>=0.041). The gemeprost group had the highest incidence of diarrhoea (38.5%) compared to misoprostol 400 µg (10.0%; <i>p</i>=0.004) and misoprostol 200 µg (8.1%; <i>p</i>=0.003) groups.</p><p><strong>Conclusions: </strong>Intravaginal misoprostol 400 µ g at 4- hour intervals was the most effective regimen but was associated with a high incidence of fever. Misoprostol 200 µg demonstrated similar effectiveness as gemeprost and had lower incidence of diarrhoea. Gemeprost should not be first line for medical therapy given the cost, storage requirements and lower efficacy.</p>","PeriodicalId":15734,"journal":{"name":"Journal of Family Planning and Reproductive Health Care","volume":" ","pages":"252-259"},"PeriodicalIF":0.0,"publicationDate":"2017-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1136/jfprhc-2016-101652","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34932143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between area deprivation and prescription of long-acting reversible contraception in women of reproductive age in Lothian, Scotland, UK.","authors":"Catherine Rachel Morgan,&nbsp;Hanhua Liu","doi":"10.1136/jfprhc-2016-101553","DOIUrl":"https://doi.org/10.1136/jfprhc-2016-101553","url":null,"abstract":"<p><strong>Background: </strong>Reducing unplanned pregnancy in Scotland is a key government objective. Long-acting reversible contraception (LARC) is a cost-effective way to reduce unintended pregnancy. Abortion and teenage pregnancy rates are highest in the most deprived areas. One possible explanation could be contraceptive prescribing inequality. This study examined the relationship between area deprivation measured by the Scottish Index of Multiple Deprivation and LARC prescription.</p><p><strong>Methods: </strong>Using Scottish electronic prescribing data from primary care and sexual and reproductive health clinics, this study analysed female Lothian residents with a valid postcode aged 16-49 years who received a contraceptive prescription from 1 April 2012 to 31 March 2014. Prescription of LARC (intrauterine, implant or injectable contraceptive) compared with non-LARC (oral pill, patch, ring or diaphragm) was examined. Logistic regression was performed adjusting for age group and prescription location.</p><p><strong>Results: </strong>A total of 90 150 women were included; 21.1% of prescriptions were LARC and 15.3% vLARC (intrauterine method or implant). Women residing in the most deprived quintile (Q1) and prescribed contraception received a significantly higher proportion of LARC than quintiles 2-5 (Q2-5). Odds ratios compared with Q1 were: Q2 0.86, Q3 0.77, Q4 0.59 and Q5 0.51. Women in quintile 1 were also significantly more likely to receive vLARC than quintiles 2-5.</p><p><strong>Conclusion: </strong>Women in the most deprived quintile in Lothian who are prescribed contraception are significantly more likely to receive LARC and vLARC compared with women in less deprived quintiles.</p>","PeriodicalId":15734,"journal":{"name":"Journal of Family Planning and Reproductive Health Care","volume":" ","pages":"281-288"},"PeriodicalIF":0.0,"publicationDate":"2017-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1136/jfprhc-2016-101553","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34968114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: 'Mind the gap: responding to the global funding crisis in family planning'.","authors":"","doi":"10.1783/1471189041261483corr1","DOIUrl":"https://doi.org/10.1783/1471189041261483corr1","url":null,"abstract":"","PeriodicalId":15734,"journal":{"name":"Journal of Family Planning and Reproductive Health Care","volume":" ","pages":"345"},"PeriodicalIF":0.0,"publicationDate":"2017-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1783/1471189041261483corr1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35439544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors' response to 'Comment on 'Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial' '.","authors":"G Justus Hofmeyr,&nbsp;Theresa Anne Lawrie","doi":"10.1136/jfprhc-2017-101864","DOIUrl":"https://doi.org/10.1136/jfprhc-2017-101864","url":null,"abstract":"We thank Quispe Calla and colleagues for their insightful comments1 on our article.2 We agree that basic science evidence showing that various progestogens increase HIV susceptibility is compelling. We also agree that randomised clinical trials (RCTs) are informative regarding the relative risks of HIV between contraceptive alternatives, but not the absolute risks …","PeriodicalId":15734,"journal":{"name":"Journal of Family Planning and Reproductive Health Care","volume":" ","pages":"344"},"PeriodicalIF":0.0,"publicationDate":"2017-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1136/jfprhc-2017-101864","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35439545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 'My Body Back' Clinic: a specialist cervical screening and sexually transmitted infection testing clinic for women who have been sexually abused.","authors":"Jill M Zelin,&nbsp;Louise Cadman,&nbsp;Pavan Amara,&nbsp;Siobhan Marnoch,&nbsp;Jane Vosper","doi":"10.1136/jfprhc-2017-101741","DOIUrl":"https://doi.org/10.1136/jfprhc-2017-101741","url":null,"abstract":"The 'My Body Back' (MBB) Clinic at St Bartholomew's Hospital in London, UK was awarded the 2016 Faculty of Sexual & Reproductive Health Care (FSRH) David Bromham Annual Memorial Award for work that has furthered the practice of sexual and reproductive healthcare through inspiration, innovation and energy. This article is adapted from the authors' presentation delivered at the FSRH Current Choices Conference 2016 and describes the clinic and its rationale. Further articles describing the service evaluation and clinical outcomes are in preparation.\u0000\u0000The My Body Back Project helps women who have experienced sexual violence. These women often feel isolated, traumatised and unable to access healthcare.1 Founded in August 2015, the MBB Clinic is a unique cervical screening clinic designed for such women.\u0000\u0000One in five women does not attend for cervical screening; among these are those who have experienced sexual violence.2–4 There is evidence to suggest that sexually abused women may be at increased risk of cervical cancer and avoid healthcare, including cervical screening.5–8 Pavan Amara set up the MBB Project as a result of her own experiences following rape. Pavan, a freelance journalist, interviewed women who had experienced sexual violence, and research nurse Louise Cadman separately carried out a study in this group of women, researching access and uptake of cervical screening. Informed by the women themselves, they both reached similar conclusions regarding the need for specialised care around cervical screening for women who have experienced sexual violence. As a consequence this collaborative clinic was set up to offer these women the opportunity for equal access to healthcare.\u0000\u0000Listening to Pavan and Louise at the 2014 FSRH Current Choices Conference in London describing the difficulties for these women and highlighting the need for specialised clinical services to enable them to have their often long-overdue smears, Jill Zelin was inspired …","PeriodicalId":15734,"journal":{"name":"Journal of Family Planning and Reproductive Health Care","volume":" ","pages":"327-330"},"PeriodicalIF":0.0,"publicationDate":"2017-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1136/jfprhc-2017-101741","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35294916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Removal of Mirena^® with fibrous tissue around the arms.","authors":"Amy Elizabeth Davies","doi":"10.1136/jfprhc-2017-101870","DOIUrl":"https://doi.org/10.1136/jfprhc-2017-101870","url":null,"abstract":"I would like to share a photograph with journal readers. I removed a nulliparous woman’s Mirena® intrauterine system (IUS) recently which had been in situ for 2.5 years. The woman had been unhappy with her IUS for a year or so, as she blamed it for some intermittent pelvic pains that she …","PeriodicalId":15734,"journal":{"name":"Journal of Family Planning and Reproductive Health Care","volume":" ","pages":"347"},"PeriodicalIF":0.0,"publicationDate":"2017-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1136/jfprhc-2017-101870","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35439551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Providing experiential information on early medical abortion: a qualitative evaluation of an animated personal account, <i>Lara's Story</i>.","authors":"Sarah Sherman,&nbsp;Jeni Harden,&nbsp;Dawn Cattanach,&nbsp;Sharon T Cameron","doi":"10.1136/jfprhc-2016-101641","DOIUrl":"https://doi.org/10.1136/jfprhc-2016-101641","url":null,"abstract":"<p><strong>Background: </strong>An animated film has been created to provide information to women requesting early medical abortion (EMA). The 9 min film, <i>Lara's Story</i>, was created using one woman's personal account of her experience. This study evaluated the views of women who had recently undergone EMA on the film and its potential usefulness in providing experiential information to women requesting EMA.</p><p><strong>Method: </strong>Women who had undergone EMA within the past month were recruited. They were shown the film and interviewed in a semi-structured style. Interviews were recorded and transcribed verbatim. They were analysed using cross-sectional indexing and thematic analysis with an inductive approach.</p><p><strong>Results: </strong>13 women were interviewed. All reported that the film gave a realistic account of EMA and most agreed that they would have wanted to watch it before EMA had it been available. Some said that it might help women who were struggling with decision-making with regard to EMA and all said that there should be unrestricted access to the film from the website of the abortion service. The women commented that the animated style of the film allowed all groups of women to relate to the story. Some commented that Lara's experience of pain, bleeding and side effects such as nausea differed from their own and therefore felt that it would be useful to make more than one woman's account available.</p><p><strong>Conclusion: </strong>The availability of animated audiovisual films recounting women's experiences of EMA might be a valuable adjunct to clinical information for women seeking EMA.</p>","PeriodicalId":15734,"journal":{"name":"Journal of Family Planning and Reproductive Health Care","volume":" ","pages":"269-273"},"PeriodicalIF":0.0,"publicationDate":"2017-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1136/jfprhc-2016-101641","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35152302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}